Q3 Earnings Estimate for CBIO Issued By HC Wainwright

Key Points

• HC Wainwright has issued a Q3 2025 EPS estimate of ($1.29) for Crescent Biopharma, with a current rating of "Buy" and a target price of $25.00.
• Other analysts have varied opinions, ranging from a "sell" rating to "strong-buy," with price targets as high as $28.00.
• Crescent Biopharma recently reported earnings of ($4.93) per share, significantly missing analysts' expectations of ($2.69).

Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Crescent Biopharma in a research note issued on Monday, August 11th. HC Wainwright analyst M. Kapoor anticipates that the biopharmaceutical company will earn ($1.29) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Crescent Biopharma's current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Crescent Biopharma's Q4 2025 earnings at ($1.31) EPS, FY2025 earnings at ($8.43) EPS, Q1 2026 earnings at ($1.33) EPS, Q2 2026 earnings at ($1.36) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.42) EPS and FY2026 earnings at ($5.49) EPS.

Other analysts also recently issued reports about the company. Lifesci Capital upgraded Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price on the stock in a research note on Wednesday, June 18th. TD Cowen raised Crescent Biopharma to a "strong-buy" rating in a report on Friday, June 20th. Stifel Nicolaus initiated coverage on Crescent Biopharma in a report on Wednesday, June 25th. They set a "buy" rating and a $28.00 price target on the stock. Wedbush started coverage on Crescent Biopharma in a report on Monday, July 14th. They set an "outperform" rating and a $27.00 price target on the stock. Finally, Wall Street Zen cut Crescent Biopharma from a "hold" rating to a "sell" rating in a report on Saturday, August 2nd. One analyst has rated the stock with a sell rating, three have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $25.50.

Crescent Biopharma Stock Performance

CBIO stock remained flat at $13.79 on Wednesday. The company had a trading volume of 471,828 shares, compared to its average volume of 44,663. Crescent Biopharma has a one year low of $10.83 and a one year high of $63.00. The firm has a market capitalization of $269.59 million, a P/E ratio of -0.39 and a beta of 1.51. The stock's 50 day moving average price is $13.88.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC purchased a new position in shares of Crescent Biopharma during the second quarter valued at approximately $7,322,000. Commodore Capital LP bought a new position in Crescent Biopharma in the second quarter worth approximately $7,322,000. Soleus Capital Management L.P. acquired a new position in shares of Crescent Biopharma during the second quarter worth $6,456,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Crescent Biopharma during the second quarter worth $1,629,000. Finally, Bank of America Corp DE acquired a new position in shares of Crescent Biopharma during the second quarter worth $149,000. Hedge funds and other institutional investors own 75.19% of the company's stock.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.